Durable complete response to dual immune checkpoint blockade in an MMR-deficient, Lynch syndrome-associated CNS WHO grade 3 meningioma

Clicks: 20
ID: 330741
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #149 of 286 articles by views in journal of neuro-oncology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 286 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Lay Summary High-grade meningiomas are rare brain tumors with limited treatment options when they return after surgery and radiotherapy. We describe a patient with a recurrent meningioma associated with Lynch syndrome and genetic changes affecting the tumor’s ability to repair its DNA. The patient received two immunotherapy drugs followed by treatment with one drug alone and achieved complete disappearance of the tumor, which persisted after treatment was stopped. We also analyzed the tumor tissue collected before immunotherapy and found many active immune cells, indicating an environment potentially favorable to an immune response. This case highlights the importance of studying both tumor genetics and its immune environment.
Reference Key
openalex_W7215083106 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Marta Maccari, Elena Marinelli, Mario Caccese, Marta Padovan, Alberto Bosio, Angela Guerriero, Luisa Bellu, Giovanni Librizzi, Sara Lonardi, Susanna Mandruzzato, Giuseppe Lombardi
Are you one of these authors? Claim your profile
Journal journal of neuro-oncology
Year 2026
DOI
10.1093/neuonc/noag239
URL
https://doi.org/10.1093/neuonc/noag239
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.